Bristol Myers flunks frontline multiple myeloma trial, turning attention to cell therapy
Celgene and Bristol Myers Squibb may have combined forces, but their latest mix of multiple myeloma treatments don’t appear to be a good match. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
